Innovative Drug Discovery Aqemia utilizes cutting-edge quantum-inspired physics algorithms combined with AI to accelerate drug development, offering a competitive advantage for pharmaceutical companies seeking faster and more efficient R&D pipelines.

Strong Funding Growth With over 100 million dollars in cumulative funding and recent investments led by prominent firms like Cathay Innovation, Aqemia demonstrates solid financial backing, positioning it for expansion and increased technological deployment.

Expansion & Presence The recent opening of Aqemia’s London office and participation in global healthcare and tech conferences indicate a strategic approach to entering new markets and forming alliances within the biotech and pharma sectors.

Industry Recognition As part of the French Tech 120 program, Aqemia is recognized as a high-potential scale-up, enhancing its visibility and attractiveness for potential collaborators and strategic partners across the biotech ecosystem.

Emerging Market Opportunities With a focus on critical diseases such as immuno-oncology, Aqemia’s innovative platform is well-positioned to partner with established biotech firms looking to expand their pipelines with advanced, physics-driven drug candidates.